| Title |
Giant cell tumour of bone: new treatments in development
|
|---|---|
| Published in |
Clinical and Translational Oncology, January 2015
|
| DOI | 10.1007/s12094-014-1268-5 |
| Pubmed ID | |
| Authors |
A. López-Pousa, J. Martín Broto, T. Garrido, J. Vázquez |
| Abstract |
Giant cell tumour of bone (GCTB) is a benign osteolytic tumour with three main cellular components: multinucleated osteoclast-like giant cells, mononuclear spindle-like stromal cells (the main neoplastic components) and mononuclear cells of the monocyte/macrophage lineage. The giant cells overexpress a key mediator in osteoclastogenesis: the RANK receptor, which is stimulated in turn by the cytokine RANKL, which is secreted by the stromal cells. The RANK/RANKL interaction is predominantly responsible for the extensive bone resorption by the tumour. Historically, standard treatment was substantial surgical resection, with or without adjuvant therapy, with recurrence rates of 20-56 %. Studies with denosumab, a monoclonal antibody that specifically binds to RANKL, resulted in dramatic treatment responses, which led to its approval by the United States Food and Drugs Administration (US FDA). Recent advances in the understanding of GCTB pathogenesis are essential to develop new treatments for this locally destructive primary bone tumour. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | <1% |
| Italy | 1 | <1% |
| Unknown | 109 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 16 | 14% |
| Student > Bachelor | 13 | 12% |
| Student > Master | 12 | 11% |
| Student > Doctoral Student | 8 | 7% |
| Student > Ph. D. Student | 7 | 6% |
| Other | 20 | 18% |
| Unknown | 35 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 61 | 55% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Veterinary Science and Veterinary Medicine | 1 | <1% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | <1% |
| Unspecified | 1 | <1% |
| Other | 5 | 5% |
| Unknown | 40 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2015.
All research outputs
#15,315,142
of 22,778,347 outputs
Outputs from Clinical and Translational Oncology
#672
of 1,296 outputs
Outputs of similar age
#209,258
of 351,991 outputs
Outputs of similar age from Clinical and Translational Oncology
#8
of 11 outputs
Altmetric has tracked 22,778,347 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,296 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,991 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.